Laurus Labs Limited LAURUSLABS NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.lauruslabs.com

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Market & Price

Market Cap

₹73,546.19 Cr

Current Price

₹1,362.00

High / Low (52W)

₹1,381.70 / ₹608.49

Beta

0.35

Valuation

Stock P/E

86.97

Industry PE

37.60

Forward P/E

57.11

PEG Ratio

Book Value

₹98.16

Price to Book

13.87

P/S

10.80

EV/EBITDA

42.79

Dividend Yield

0.18%

Profitability & Returns

ROCE

11.92%

ROE

17.74%

ROA

8.17%

Profit Margin

13.05%

Op Margin

21.53%

EPS (Latest Qtr)

₹4.65

EPS (TTM)

₹15.66

Balance Sheet & Liquidity

Debt/Equity

0.46

Quick Ratio

0.62

Current Ratio

1.33

Debt

₹2,518.48 Cr

Total Assets

₹9,335.57 Cr

Current Assets

₹4,332.32 Cr

Working Capital

₹792.60 Cr

Ownership

Promoter Holding

32.06%

Chg in Prom Hold

FII / Inst Holding

30.86%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹76,073.54 Cr

Total Revenue (TTM)

₹6,812.90 Cr

EBITDA

₹1,777.71 Cr

Free Cash Flow

₹-46.01 Cr

Operating Cash Flow

₹1,623.50 Cr

Shares Outstanding

₹53.99 Cr

Gross Margin

60.44%

Payout Ratio

10.25%

Growth (CAGR)

Revenue 5Y

4.06%

Profit 5Y

-24.35%

Revenue (YoY)

5.30%

Earnings (YoY)

19.40%

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 87.0.
Earnings shrank at -24.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	1,362.00	86.97	₹73,546.19 Cr	0.18%	11.92%	17.74%	4.06%	-24.35%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025
Revenue	1,223.70 Cr	1,415.05 Cr	1,674.20 Cr	1,569.57 Cr	1,778.29 Cr
Cost of Revenue	548.30 Cr	610.15 Cr	844.11 Cr	637.35 Cr	694.57 Cr
Gross Profit	675.40 Cr	804.90 Cr	830.09 Cr	932.22 Cr	1,083.72 Cr
Operating Expenses	604.58 Cr	625.84 Cr	519.93 Cr	666.93 Cr	724.13 Cr
Operating Income	70.82 Cr	179.06 Cr	310.16 Cr	265.29 Cr	359.59 Cr
EBITDA	182.93 Cr	294.57 Cr	469.77 Cr	392.56 Cr	485.97 Cr
Interest Expense	52.61 Cr	57.80 Cr	46.99 Cr	51.50 Cr	38.79 Cr
Pretax Income	22.81 Cr	130.68 Cr	312.34 Cr	224.22 Cr	326.56 Cr
Tax Provision	5.09 Cr	40.07 Cr	78.47 Cr	63.14 Cr	73.45 Cr
Net Income	19.84 Cr	92.30 Cr	233.67 Cr	163.02 Cr	251.66 Cr
Diluted EPS	0.37	1.71	-	3.02	4.65

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	4,888.54 Cr	6,014.22 Cr	5,001.80 Cr	5,507.86 Cr
Cost of Revenue	2,248.32 Cr	2,840.71 Cr	2,499.09 Cr	2,539.41 Cr
Gross Profit	2,640.22 Cr	3,173.51 Cr	2,502.71 Cr	2,968.45 Cr
Operating Expenses	1,467.59 Cr	1,879.24 Cr	2,107.84 Cr	2,343.27 Cr
Operating Income	1,172.63 Cr	1,294.27 Cr	394.87 Cr	625.18 Cr
EBITDA	1,411.10 Cr	1,555.91 Cr	792.70 Cr	1,120.98 Cr
Interest Expense	75.76 Cr	122.89 Cr	171.76 Cr	206.59 Cr
Pretax Income	1,083.85 Cr	1,108.94 Cr	236.36 Cr	484.29 Cr
Tax Provision	251.42 Cr	312.30 Cr	68.15 Cr	129.88 Cr
Net Income	827.52 Cr	790.11 Cr	160.55 Cr	358.32 Cr
Diluted EPS	15.35	14.64	2.97	6.64

Compounded Sales Growth

5 Years:	4.06%
1 Year:	5.30%

Compounded Profit Growth

5 Years:	-24.35%
1 Year:	19.40%

Stock Price Performance

1 Year:	+122.05%
6 Months:	+39.18%
3 Months:	+34.05%
1 Month:	+23.26%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	6,968.04 Cr	7,660.40 Cr	8,387.03 Cr	9,335.57 Cr
Current Assets	3,344.61 Cr	3,461.68 Cr	3,834.97 Cr	4,332.32 Cr
Cash & Equivalents	75.58 Cr	45.67 Cr	138.94 Cr	99.54 Cr
Inventory	1,760.30 Cr	1,684.81 Cr	1,845.41 Cr	1,936.54 Cr
Receivables	1,354.18 Cr	1,580.44 Cr	1,662.92 Cr	2,007.16 Cr
Total Liabilities	3,608.99 Cr	3,611.74 Cr	4,271.46 Cr	4,733.05 Cr
Current Liabilities	2,681.01 Cr	2,432.26 Cr	3,112.28 Cr	3,539.72 Cr
Long Term Debt	596.34 Cr	761.42 Cr	798.23 Cr	645.58 Cr
Total Debt	1,776.66 Cr	2,015.09 Cr	2,577.40 Cr	2,763.73 Cr
Total Equity	3,351.19 Cr	4,037.53 Cr	4,110.95 Cr	4,472.56 Cr
Shares Outstanding	53.74 Cr	53.87 Cr	53.90 Cr	53.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	911.10 Cr	993.90 Cr	665.69 Cr	601.65 Cr
Investing Cash Flow	-914.34 Cr	-996.06 Cr	-822.42 Cr	-681.72 Cr
Financing Cash Flow	30.26 Cr	-26.64 Cr	249.83 Cr	39.28 Cr
Capital Expenditure	-876.84 Cr	-990.16 Cr	-678.31 Cr	-641.00 Cr
Free Cash Flow	34.26 Cr	3.74 Cr	-12.62 Cr	-39.35 Cr
Net Change in Cash	27.02 Cr	-28.80 Cr	93.10 Cr	-40.79 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	54.0%	52.8%	50.0%	53.9%
Operating Margin %	24.0%	21.5%	7.9%	11.4%
Net Margin %	16.9%	13.1%	3.2%	6.5%
ROE %	24.7%	19.6%	3.9%	8.0%
ROCE %	27.4%	24.8%	7.5%	10.8%

Shareholding Pattern

Insiders

32.06%

Institutions

30.86%

Public Float

45.42%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LAURUSLABS

No recent headlines available.

LAURUSLABS · Healthcare